A Review of Western and Traditional Chinese Medical Approaches to Managing Nonalcoholic Fatty Liver Disease

被引:12
作者
Hsu, Wei-Fan [1 ]
Sheen, Lee-Yan [2 ]
Lin, Hung-Jen [3 ]
Chang, Hen-Hong [3 ,4 ,5 ]
机构
[1] China Med Univ Hosp, Div Hepatogastroenterol, Dept Internal Med, Taichung, Taiwan
[2] Natl Taiwan Univ, Inst Food Sci & Technol, Taipei, Taiwan
[3] China Med Univ, Sch Postbaccalaureate Chinese Med, Coll Chinese Med, Taichung, Taiwan
[4] China Med Univ Hosp, Dept Chinese Med, Taichung, Taiwan
[5] China Med Univ, Res Ctr Chinese Med & Acupuncture, Taichung, Taiwan
关键词
AMELIORATES HEPATIC STEATOSIS; ACTIVATED PROTEIN-KINASE; LIPID-ACCUMULATION; BLADDER-CANCER; SCORING SYSTEM; PPAR-ALPHA; FIBROSIS; STEATOHEPATITIS; PREVALENCE; VALIDATION;
D O I
10.1155/2016/6491420
中图分类号
R [医药、卫生];
学科分类号
10 ;
摘要
Nonalcoholic fatty liver disease (NAFLD) is a disease of attention because of increase in prevalence from 20% to 41%. The clinical and pathological conditions in patients with NAFLD range from steatosis alone to nonalcoholic steatohepatitis (NASH) with or without fibrosis to hepatic cancer. In the United States, NAFLD was the second-leading indication for liver transplant between 2004 and 2013. Although imaging studies such as magnetic resonance elastography and the use of diagnostic panels and scoring systems can provide a fairly accurate diagnosis of NAFLD, there are few treatment options for patients with mild to moderate disease other than lifestyle modification. Many of the currently used medical treatments have been shown to cause severe side effects and some have been shown to be associated with increased risk for certain types of cancer. In recent years, a number of traditional Chinese herbal treatments have been examined for their potential uses as treatment for NAFLD. In this review, we provide a general overview of NAFLD and a survey of Western pharmacologic drugs currently used to treat the disease as well as the results of recent studies on the effectiveness of traditional Chinese herbal remedies for managing nonalcoholic fatty liver disease.
引用
收藏
页数:12
相关论文
共 84 条
[1]   Independent predictors of liver fibrosis in patients with nonalcoholic steatohepatitis [J].
Angulo, P ;
Keach, JC ;
Batts, KP ;
Lindor, KD .
HEPATOLOGY, 1999, 30 (06) :1356-1362
[2]   The NAFLD fibrosis score: A noninvasive system that identifies liver fibrosis in patients with NAFLD [J].
Angulo, Paul ;
Hui, Jason M. ;
Marchesini, Giulio ;
Bugianesi, Ellisabetta ;
George, Jacob ;
Farrell, Geoffrey C. ;
Enders, Felicity ;
Saksena, Sushma ;
Burt, Alastair D. ;
Bida, John P. ;
Lindor, Keith ;
Sanderson, Schuyler O. ;
Lenzi, Marco ;
Adams, Leon A. ;
Kench, James ;
Therneau, Terry M. ;
Day, Christopher P. .
HEPATOLOGY, 2007, 45 (04) :846-854
[3]  
[Anonymous], WHO traditional medicine strategy: 2014-2023
[4]  
[Anonymous], NAT REV GASTROLENTER
[5]   Glucagon-like peptide 1 decreases lipotoxicity in non-alcoholic steatohepatitis [J].
Armstrong, Matthew J. ;
Hull, Diana ;
Guo, Kathy ;
Barton, Darren ;
Hazlehurst, Jonathan M. ;
Gathercole, Laura L. ;
Nasiri, Maryam ;
Yu, Jinglei ;
Gough, Stephen C. ;
Newsome, Philip N. ;
Tomlinson, Jeremy W. .
JOURNAL OF HEPATOLOGY, 2016, 64 (02) :399-408
[6]   Liraglutide safety and efficacy in patients with non-alcoholic steatohepatitis (LEAN): a multicentre, double-blind, randomised, placebo-controlled phase 2 study [J].
Armstrong, Matthew James ;
Gaunt, Piers ;
Aithal, Guruprasad P. ;
Barton, Darren ;
Hull, Diana ;
Parker, Richard ;
Hazlehurst, Jonathan M. ;
Guo, Kathy ;
Abouda, George ;
Aldersley, Mark A. ;
Stocken, Deborah ;
Gough, Stephen C. ;
Tomlinson, Jeremy W. ;
Brown, Rachel M. ;
Huebscher, Stefan G. ;
Newsome, Philip N. .
LANCET, 2016, 387 (10019) :679-690
[7]   The use of pioglitazone and the risk of bladder cancer in people with type 2 diabetes: nested case-control study [J].
Azoulay, Laurent ;
Yin, Hui ;
Filion, Kristian B. ;
Assayag, Jonathan ;
Majdan, Agnieszka ;
Pollak, Michael N. ;
Suissa, Samy .
BMJ-BRITISH MEDICAL JOURNAL, 2012, 344
[8]   Utility and Appropriateness of the Fatty Liver Inhibition of Progression (FLIP) Algorithm and Steatosis, Activity, and Fibrosis (SAF) Score in the Evaluation of Biopsies of Nonalcoholic Fatty Liver Disease [J].
Bedossa, Pierre .
HEPATOLOGY, 2014, 60 (02) :565-575
[9]   Meta-Regression Analyses, Meta-Analyses, and Trial Sequential Analyses of the Effects of Supplementation with Beta-Carotene, Vitamin A, and Vitamin E Singly or in Different Combinations on All-Cause Mortality: Do We Have Evidence for Lack of Harm? [J].
Bjelakovic, Goran ;
Nikolova, Dimitrinka ;
Gluud, Christian .
PLOS ONE, 2013, 8 (09)
[10]  
Brunt EM, 1999, AM J GASTROENTEROL, V94, P2467, DOI 10.1111/j.1572-0241.1999.01377.x